Abstract: EP1388
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - MS symptoms
Background: Natural history studies in MS largely focused on determining time-to-disability benchmarks. Little is known about changes in MS symptom burden from patient's point of view. SymptoMScreen is an in-house developed and validated patient-reported outcome (PRO) tool for assessing symptom severity in 12 domains commonly affected by MS - walking, dexterity, spasticity, bodily pain, sensory, bladder, fatigue, vision, dizziness, cognitive, depression and anxiety. SymptoMScreen is collected on all patients at each visit in our MS Centers and can be used to track disease impact as perceived by the patient.
Objective: To report on longitudinal changes in total and domain SymptoMScreen scores in MS patients attending two tertiary MS centres.
Methods: SymptoMScreen is collected on all patients attending NYU or Barnabas MS Care Centers as part of routine clinical care. We retroactively analysed responses in our patients who were age 18 or older, had clinician-diagnosed MS (McDonald criteria) and fully completed 2 or more SyMS questionnaires over a period of ≥12 months.
Results: 594 MS patients (72.3% women) satisfied our inclusion criteria. At baseline, mean age was 44.1 (±12.3) and disease duration was 10.8 (±9.1). Follow up period was 16.7 (±3.7) months (range 12-38). Average disability at baseline, assessed by Patient-Determined Disease Steps (PDDS) was 1.9 (±2.0) (range 0 to 7; scores of 3 or more correspond to worsening ambulatory dysfunction and motor disability). PDDS at last follow up was 2.0 (±2.1) (range 0-7), an increase of 0.1 points, paired t-test p=0.012. Mean total SymptoMScreen score at baseline was 17.3 (±14.3), and at last follow up - 18.1 (±14.9), an increase of 0.7, paired t-test p=0.034. Domain SymptoMScreen significantly increased in bladder p< 0.001, hand p=0.044 and dizziness p=0.050 domains and did not significantly increase in the other domains. In a multivariable regression analysis with age, gender, time between assessments and baseline symptoMScreen, only baseline total SymptoMScreen was a significant predictor of the final total SymptoMScreen score.
Conclusions: Overall symptoms botheration, as assessed with multi-dimensional SymptoMScreen, has increased modestly but significantly over the period of observation of ~16 months, in parallel with increase in patient-rated disability score. Changes in SymptoMScreen domain scores varied across symptoms and were significant in bladder, dexterity and dizziness domains.
Disclosure: Ilya Kister served on scientific advisory board for Biogen Idec and Genentech and received research support from Guthy-Jackson Charitable Foundation, National Multiple Sclerosis Society, Biogen-Idec,Serono, Genzyme and Novartis.
Tamar Bacon has nothing to disclose.
Gary Cutter has served on data and safety monitoring boards for AMO Pharmaceuticals, Apotek, Horizon Pharmaceuticals, Merck, Merck/Pfizer, Modigenetech/Prolor, Neurim, Opko Biologics, Reata Pharmaceuticals, Receptos/Celgene, Sanofi, Teva Pharmaceuticals, NHLBI (Protocol Review Committee), and NICHD (OPRU oversight committee); has received compensation for consulting or advisory boards from Argenix, Atara Biotherapeutics, Bioeq GmBH, the Consortium of MS Centers (grant), Genzyme, Genentech, Innate Therapeutics, Klein-Buendel Incorporated, MedDay, Medimmune, Novartis, Opexa Therapeutics, Roche, Savara Inc., Somahlution, Teva Pharmaceuticals, TG Therapeutics, and Transparency Life Sciences; and is president of Pythagoras, Inc., a private consulting company.
Abstract: EP1388
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - MS symptoms
Background: Natural history studies in MS largely focused on determining time-to-disability benchmarks. Little is known about changes in MS symptom burden from patient's point of view. SymptoMScreen is an in-house developed and validated patient-reported outcome (PRO) tool for assessing symptom severity in 12 domains commonly affected by MS - walking, dexterity, spasticity, bodily pain, sensory, bladder, fatigue, vision, dizziness, cognitive, depression and anxiety. SymptoMScreen is collected on all patients at each visit in our MS Centers and can be used to track disease impact as perceived by the patient.
Objective: To report on longitudinal changes in total and domain SymptoMScreen scores in MS patients attending two tertiary MS centres.
Methods: SymptoMScreen is collected on all patients attending NYU or Barnabas MS Care Centers as part of routine clinical care. We retroactively analysed responses in our patients who were age 18 or older, had clinician-diagnosed MS (McDonald criteria) and fully completed 2 or more SyMS questionnaires over a period of ≥12 months.
Results: 594 MS patients (72.3% women) satisfied our inclusion criteria. At baseline, mean age was 44.1 (±12.3) and disease duration was 10.8 (±9.1). Follow up period was 16.7 (±3.7) months (range 12-38). Average disability at baseline, assessed by Patient-Determined Disease Steps (PDDS) was 1.9 (±2.0) (range 0 to 7; scores of 3 or more correspond to worsening ambulatory dysfunction and motor disability). PDDS at last follow up was 2.0 (±2.1) (range 0-7), an increase of 0.1 points, paired t-test p=0.012. Mean total SymptoMScreen score at baseline was 17.3 (±14.3), and at last follow up - 18.1 (±14.9), an increase of 0.7, paired t-test p=0.034. Domain SymptoMScreen significantly increased in bladder p< 0.001, hand p=0.044 and dizziness p=0.050 domains and did not significantly increase in the other domains. In a multivariable regression analysis with age, gender, time between assessments and baseline symptoMScreen, only baseline total SymptoMScreen was a significant predictor of the final total SymptoMScreen score.
Conclusions: Overall symptoms botheration, as assessed with multi-dimensional SymptoMScreen, has increased modestly but significantly over the period of observation of ~16 months, in parallel with increase in patient-rated disability score. Changes in SymptoMScreen domain scores varied across symptoms and were significant in bladder, dexterity and dizziness domains.
Disclosure: Ilya Kister served on scientific advisory board for Biogen Idec and Genentech and received research support from Guthy-Jackson Charitable Foundation, National Multiple Sclerosis Society, Biogen-Idec,Serono, Genzyme and Novartis.
Tamar Bacon has nothing to disclose.
Gary Cutter has served on data and safety monitoring boards for AMO Pharmaceuticals, Apotek, Horizon Pharmaceuticals, Merck, Merck/Pfizer, Modigenetech/Prolor, Neurim, Opko Biologics, Reata Pharmaceuticals, Receptos/Celgene, Sanofi, Teva Pharmaceuticals, NHLBI (Protocol Review Committee), and NICHD (OPRU oversight committee); has received compensation for consulting or advisory boards from Argenix, Atara Biotherapeutics, Bioeq GmBH, the Consortium of MS Centers (grant), Genzyme, Genentech, Innate Therapeutics, Klein-Buendel Incorporated, MedDay, Medimmune, Novartis, Opexa Therapeutics, Roche, Savara Inc., Somahlution, Teva Pharmaceuticals, TG Therapeutics, and Transparency Life Sciences; and is president of Pythagoras, Inc., a private consulting company.